The ARCTIC trial (NCT02352948) evaluated the safety and clinical outcome of administering durvalumab, an anti-PD-L1 antibody, as monotherapy and combined with tremelimumab in patients with advanced NSCLC (127). The gene discussed is CD274; the disease is non-small cell lung carcinoma.